Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1997 Jun;62(6):622–625. doi: 10.1136/jnnp.62.6.622

[18F]fluorodopa PET shows striatal dopaminergic dysfunction in juvenile neuronal ceroid lipofuscinosis.

H M Ruottinen 1, J O Rinne 1, M Haaparanta 1, O Solin 1, J Bergman 1, V J Oikonen 1, I Järvelä 1, P Santavuori 1
PMCID: PMC1074148  PMID: 9219750

Abstract

OBJECTIVES: To investigate whether nigrostriatal dopaminergic hypofunction is related to the extrapyramidal symptoms in patients with juvenile neuronal ceroid lipofuscinosis (JNCL). METHODS: Nine patients with JNCL and seven healthy controls were studied using [18F]fluorodopa PET. RESULTS: In the patients with JNCL [18F]fluorodopa uptake (K[i][occ]) in the putamen was 60% of the control mean and the corresponding figure in the caudate nucleus was 79%. There was a weak correlation between putamen K(i)(occ) values and extrapyramidal symptoms of the patients evaluated by the motor part of the unified Parkinson's disease rating scale (r = -0.57, P < 0.05). The overall severity of the disease also displayed a negative correlation with the K(i)(occ) values in the putamen (r = -0.71, P < 0.05). CONCLUSION: In patients with JNCL there was reduced striatal [18F]fluorodopa uptake, which had a modest correlation with extrapyramidal symptoms. Dysfunction of nigrostriatal dopaminergic neurons is therefore not the only cause of the patients' extrapyramidal symptoms, but degenerative changes in other brain areas are also contributory.

Full text

PDF
622

Images in this article

624Image
on p.624

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Autti T., Raininko R., Vanhanen S. L., Santavuori P. MRI of neuronal ceroid lipofuscinosis. I. Cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis. Neuroradiology. 1996 Jul;38(5):476–482. doi: 10.1007/BF00607283. [DOI] [PubMed] [Google Scholar]
  2. Brooks D. J., Salmon E. P., Mathias C. J., Quinn N., Leenders K. L., Bannister R., Marsden C. D., Frackowiak R. S. The relationship between locomotor disability, autonomic dysfunction, and the integrity of the striatal dopaminergic system in patients with multiple system atrophy, pure autonomic failure, and Parkinson's disease, studied with PET. Brain. 1990 Oct;113(Pt 5):1539–1552. doi: 10.1093/brain/113.5.1539. [DOI] [PubMed] [Google Scholar]
  3. De Volder A. G., Cirelli S., de Barsy T., Brucher J. M., Bol A., Michel C., Goffinet A. M. Neuronal ceroid-lipofuscinosis: preferential metabolic alterations in thalamus and posterior association cortex demonstrated by PET. J Neurol Neurosurg Psychiatry. 1990 Dec;53(12):1063–1067. doi: 10.1136/jnnp.53.12.1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Eidelberg D., Takikawa S., Dhawan V., Chaly T., Robeson W., Dahl R., Margouleff D., Moeller J. R., Patlak C. S., Fahn S. Striatal 18F-dopa uptake: absence of an aging effect. J Cereb Blood Flow Metab. 1993 Sep;13(5):881–888. doi: 10.1038/jcbfm.1993.110. [DOI] [PubMed] [Google Scholar]
  5. Hartvig P., Agren H., Reibring L., Tedroff J., Bjurling P., Kihlberg T., Långström B. Brain kinetics of L-[beta-11C]dopa in humans studied by positron emission tomography. J Neural Transm Gen Sect. 1991;86(1):25–41. doi: 10.1007/BF01250373. [DOI] [PubMed] [Google Scholar]
  6. Iannetti P., Messa C., Spalice A., Lucignani G., Fazio F. Positron emission tomography in neuronal ceroid lipofuscinosis (Jansky-Bielschowsky disease): a case report. Brain Dev. 1994 Nov-Dec;16(6):459–462. doi: 10.1016/0387-7604(94)90008-6. [DOI] [PubMed] [Google Scholar]
  7. Järvelä I., Mitchison H. M., Munroe P. B., O'Rawe A. M., Mole S. E., Syvänen A. C. Rapid diagnostic test for the major mutation underlying Batten disease. J Med Genet. 1996 Dec;33(12):1041–1042. doi: 10.1136/jmg.33.12.1041. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Martin W. R., Palmer M. R., Patlak C. S., Calne D. B. Nigrostriatal function in humans studied with positron emission tomography. Ann Neurol. 1989 Oct;26(4):535–542. doi: 10.1002/ana.410260407. [DOI] [PubMed] [Google Scholar]
  9. Namavari M., Bishop A., Satyamurthy N., Bida G., Barrio J. R. Regioselective radiofluorodestannylation with [18F]F2 and [18F]CH3COOF: a high yield synthesis of 6-[18F]Fluoro-L-dopa. Int J Rad Appl Instrum A. 1992 Aug;43(8):989–996. doi: 10.1016/0883-2889(92)90217-3. [DOI] [PubMed] [Google Scholar]
  10. Patlak C. S., Blasberg R. G. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985 Dec;5(4):584–590. doi: 10.1038/jcbfm.1985.87. [DOI] [PubMed] [Google Scholar]
  11. Philippart M., Messa C., Chugani H. T. Spielmeyer-Vogt (Batten, Spielmeyer-Sjögren) disease. Distinctive patterns of cerebral glucose utilization. Brain. 1994 Oct;117(Pt 5):1085–1092. doi: 10.1093/brain/117.5.1085. [DOI] [PubMed] [Google Scholar]
  12. Rapola J., Santavuori P., Savilahti E. Suction biopsy of rectal mucosa in the diagnosis of infantile and juvenile types of neuronal ceroid lipofuscinoses. Hum Pathol. 1984 Apr;15(4):352–360. doi: 10.1016/s0046-8177(84)80034-9. [DOI] [PubMed] [Google Scholar]
  13. Rider J. A., Rider D. L. Batten disease: past, present, and future. Am J Med Genet Suppl. 1988;5:21–26. doi: 10.1002/ajmg.1320310606. [DOI] [PubMed] [Google Scholar]
  14. Ruottinen H. M., Rinne J. O., Ruotsalainen U. H., Bergman J. R., Oikonen V. J., Haaparanta M. T., Solin O. H., Laihinen A. O., Rinne U. K. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1995;10(2-3):91–106. doi: 10.1007/BF02251225. [DOI] [PubMed] [Google Scholar]
  15. Santavuori P., Heiskala H., Autti T., Johansson E., Westermarck T. Comparison of the clinical courses in patients with juvenile neuronal ceroid lipofuscinosis receiving antioxidant treatment and those without antioxidant treatment. Adv Exp Med Biol. 1989;266:273–282. doi: 10.1007/978-1-4899-5339-1_19. [DOI] [PubMed] [Google Scholar]
  16. Santavuori P., Heiskala H., Westermarck T., Sainio K., Moren R. Experience over 17 years with antioxidant treatment in Spielmeyer-Sjögren disease. Am J Med Genet Suppl. 1988;5:265–274. doi: 10.1002/ajmg.1320310629. [DOI] [PubMed] [Google Scholar]
  17. Santavuori P., Westermarck T., Rapola J., Pohja P., Moren R., Lappi M., Vuonnala U. Antioxidant treatment in Spielmeyer-Sjögren's disease. Acta Neurol Scand. 1985 Feb;71(2):136–145. doi: 10.1111/j.1600-0404.1985.tb03178.x. [DOI] [PubMed] [Google Scholar]
  18. Sawle G. V., Colebatch J. G., Shah A., Brooks D. J., Marsden C. D., Frackowiak R. S. Striatal function in normal aging: implications for Parkinson's disease. Ann Neurol. 1990 Dec;28(6):799–804. doi: 10.1002/ana.410280611. [DOI] [PubMed] [Google Scholar]
  19. Zweije-Hofman I. L., van der Zee H. J., van Nieuwenhuizen O. Anti-parkinson drugs in the Batten-Spielmeyer-Vogt syndrome; a pilot trial. Clin Neurol Neurosurg. 1982;84(2):101–105. doi: 10.1016/0303-8467(82)90062-2. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES